Manipulation Of Internalization Property Of Cell Surface Molecules Using A Guide-Effector Bispecific Design

Value Proposition

For many therapeutics across different disease areas there is a need to improve the internalization of the therapeutic by the targeted cells.

Technology Description

UCSF investigators have engineered bispecific antibodies that are capable of co-engaging a pair of antigens, termed “guide antigen” and “effector antigen,” that are expressed on the surface of the same cell. When being co-engaged by the engineered antibodies, the guide antigen can influence cell surface dynamics and/or signaling function of the effector antigen. The efficacy of such engineered bispecific antibodies has been demonstrated in vitro and in vivo in relevant animal models in the case of pancreatic cancer.

Patent Status

Additional Patents Pending